Company intelligence / Profile preview

CTX Inc.

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

Lead program CTX-220 showed 100% response rate with -7.0 mean change in CMTNS in Phase 1 CMT study (n=9); Phase 1 DPN trial ongoing; preclinical iPSC-derived mDA for Parkinson’s.

Therapeutic areas: EndocrinologyNeurology
Modalities: Cell therapy
Industry: Biotech

Partnerships

Seeking partners for clinical co-development

Beyond the preview

Go deeper on CTX Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTX Inc..

Explore the full profile